High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

BACKGROUND: Eribulin, a nontaxane synthetic inhibitor of microtubule dynamics, is widely used to manage locally advanced or metastatic breast cancer (MBC). Eribulin has demonstrated immunomodulatory activity on the tumour microenvironment. Baseline neutrophil-to-lymphocyte ratio (NLR), a marker of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Yasuo, Yoshimura, Yuta, Saito, Kenichi, Muramoto, Kenzo, Sugawara, Michiko, Alexis, Karenza, Nomoto, Kenichi, Nakamura, Seigo, Saeki, Toshiaki, Watanabe, Junichiro, Perez-Garcia, Jose Manuel, Cortes, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297864/
https://www.ncbi.nlm.nih.gov/pubmed/32133606
http://dx.doi.org/10.1007/s12282-020-01067-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297864/
https://www.ncbi.nlm.nih.gov/pubmed/32133606
http://dx.doi.org/10.1007/s12282-020-01067-2

Ejemplares similares